Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

Karen Huger revealed whether she's using Ozempic, explaining she's using a medication for a reason other than weight loss. Learn more.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Read here for a detailed financial analysis of Medifast stock post-pandemic, GLP-1 impact, and the company's collaboration ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...